Figure 1.

PPM1D expression between AML patients and health donors. The comparison of PPM1D mRNA relative expression between AML patients and healthy donors (A). The performance of PPM1D mRNA relative expression in distinguishing AML patients from healthy donors (B). Representative Western blot images exhibiting the PPM1D protein relative expression in AML patients and healthy donors (C). The comparison of PPM1D protein relative intensity between AML patients and healthy donors (D). The performance of PPM1D protein relative intensity in distinguishing AML patients from healthy donors (E). Comparisons of PPM1D mRNA/protein expression between two groups were determined by Wilcoxon rank‐sum test. ROC curves and the AUC with 95% CI were used to assess the ability of PPM1D mRNA/protein in discriminating AML and healthy donors. P value < .05 was considered significant. AML, acute myeloid leukemia; mRNA, messenger RNA; AUC, area under the curve; CI, confidence interval; PPM1D, protein phosphatase Mg²⁺/Mn²⁺ dependent 1D; ROC, receiver operating characteristic